Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2409298 | Vaccine | 2006 | 9 Pages |
Abstract
Therapeutic vaccination of mice bearing melanoma tumors with our genetically modified tumor cells, via DOTAP/GM-CSF lipoplexes, results in >85% tumor growth inhibition. These fresh transfected cells (irradiated, frozen and thawed) are able to produce high amounts of GM-CSF transgene (>200Â ng/106Â cells/24Â h). After vaccination, significant increases (>eight-fold) in specific antitumor membrane protein IgG1 and IgG2a are obtained only in groups vaccinated with GM-CSF-producing cells, where also the highest rates of tumor inhibition, and significantly delayed mice death (PÂ <Â 0.05), are observed. The antitumor response obtained is long-lasting in survivors (GM-CSF-group) from 6 months after the first tumor challenge, and a full 100% of mice survived to a second tumor challenge. All these results suggest that antitumor cell vaccines engineered by nonviral procedures are suitable for use as therapeutic vaccines with potential clinical applications.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Inés Moret-Tatay, IsaÃas SanmartÃn, Francisco M. Marco, JoaquÃn DÃaz, Salvador F. Aliño,